Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
Yun Wu(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), You‐Lin Qiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiayu Wang(Nanjing University of Chinese Medicine), Pei Yu(Shanghai Jiao Tong University), Huawei Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Min Yan(Zhengzhou University), Li Cai(Wenzhou Medical University), Tao Sun(Wuhan University), Xinlan Liu(Yunnan Agricultural University), Xichun Hu(Fudan University Shanghai Cancer Center), Tao Huang(Union Hospital), Yuee Teng(First Hospital of China Medical University), Yongmei Yin(Nanjing Medical University), Zhongsheng Tong(Institute of Oncology NN Petrov), Yang Shun-e(Xinjiang Medical University), Xi Chen, Hui Li(First Affiliated Hospital of Zhengzhou University), Shusen Wang(Sun Yat-sen University), Xiaojia Wang(Wenzhou Medical University), Hongyuan Li(Central South University), Runxiang Yang(Kunming Medical University), Quchang Ouyang(Hunan Cancer Hospital), Jianjun He(Hebei Medical University), Yiqun Han(Mayo Clinic), Jin‐Hu Fan(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 6
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k